VA
Personalis Q3 Revenues Down 33 Percent on Disputed VA Contract
The revenue drop reflects a hold on the company's ongoing contract to provide sequencing services for the US Department of Veterans Affairs.
Natera Awarded Contract to Provide Cancer Testing Services to VA
Natera will provide the VA with its Signatera circulating tumor DNA test for minimal residual disease assessment and treatment monitoring.
Biodesix Nabs US Federal Supply Schedule Contract for Lung Cancer Tests
The company's full lung cancer diagnostic menu will be covered for eligible veterans, active-duty military, and their families.
Oncocyte Nets $3M VA Contract for DetermaRx Lung Cancer Prognostic Test
The test will be covered by the VA for five years to determine the risk of recurrence in early-stage lung cancer patients after surgery.
Grail, Veterans Affairs to Evaluate Galleri Cancer Early Detection Test
Grail will make Galleri available to 10,000 veterans, who may then participate in the company's observational REFLECTION study.
Aug 4, 2021
Personalis Q2 Revenues Rise 11 Percent
May 5, 2021
Personalis Q1 Revenues Grow 9 Percent
Nov 5, 2020
Personalis Q3 Revenues Up 16 Percent
Aug 6, 2020
Personalis Q2 Revenues Up 23 Percent
May 7, 2020
Personalis Q1 Revenues Up 36 Percent
Nov 13, 2019